MHRA confirms supply of medical cannabis product until 2023

Cannabis News World

Sep 6

MHRA confirms supply of medical cannabis product until 2023
Cannabis Health News

UK patients will be able to access the medical cannabis oil, Celixir20 until 2023, while a permanent solution is reached, regulators have confirmed. The Medicines and Health Regulatory Agency (MHRA) has confirmed that it will continue accepting applications for the importation of a medical cannabis oil, prescribed to children with epilepsy, until the end of the year. In a statement to Cannabis Health, the regulator said no parent should have "cause for concern about ongoing supplies". Patients prescribed the product through private clinics in the UK, recently learned that the regulator would no longer be allowing imports from the Israeli manufacturer, Bol Pharma, as its licence did not meet EU Good Manufacturing Practices (GMP) standards. However, the MHRA is now said to have agreed measures to enable the importer to continue to supply UK patients until 2023, while a "permanent resolution" is reached. Celixir20, which contains 20:1 CBD to THC, is thought to be prescribed to around 30 children with severe epilepsy in the UK. A number of other adult patients use the oil for symptoms such as chronic pain and anxiety. Dr Laura Squire, MHRA Chief Healthcare, Quality and Access Officer said: "We recognise the importance of these cannabis oil products for children with severe forms of epilepsy. "That is why we are enabling continued patient access to them by accepting applications to import. No parent should have cause for concern about ongoing supplies." What happens next? The update means regulators now have six months to work towards a solution, or patients will be faced with having to find an alternative medicine. READ MORE: It is "highly unsafe" to switch children's cannabis medicines, says leading epilepsy expert Experts say that there is currently no other product on the market which is similar in strength and chemovar profile to Celixir20,…